Position in MGNX
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$7,588,932
+$5,862,325 QoQ
Shares Held
1,642,626
+174.9% QoQ
Ownership
2.58%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#12
of 122 holders
Holding Since
Jun 2022
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in MGNX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026MACKENZIE FINANCIAL CORP holds $499,025,453 across 60 Biotechnology names. MGNX ranks #16 (1.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
135,783 | $84,666,131 | |
| 2 | INCY |
Incyte Corp
|
634,862 | $71,967,956 | |
| 3 | BMRN |
Biomarin Pharmaceutical Inc
|
931,864 | $53,321,258 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
102,928 | $51,127,425 | |
| 5 | BBIO |
BridgeBio Pharma, Inc.
|
298,440 | $22,227,811 | |
| 6 | TBPH |
Theravance Biopharma, Inc.
|
985,848 | $16,759,416 | |
| 7 | RPRX |
Royalty Pharma plc
|
270,457 | $15,164,523 | |
| 8 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
43,988 | $13,241,707 |
All Filings in MGNX
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $7,588,932 | 1,642,626 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $1,726,607 | 597,442 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $334,685 | 207,879 | Shares | Sole | 2026-02-18 | |
| 2022-09-30 | $37,219 | 10,757 | Shares | Sole | 2022-10-07 | |
| 2022-06-30 | $37,364 | 12,666 | Shares | Sole | 2022-08-10 | |
| No filing history on record for this holder in this stock. | ||||||